A Phase 2 interventional study of Eltrombopag in Aplastic Anemia, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 11 in phase 2, and was the 12th registered.
372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.
Browse Anemia, Aplastic studies →3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
Melbourne Health · Sites in Australia
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 4
First in 2009; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 36 across the 17 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
14 studies in Anemia, Aplastic by Novartis: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 7 (58%) have results posted.
Among the 14 studies in Anemia, Aplastic by Novartis, this one is the only one that started in 2019, is one of 7 in phase 2, and was the 8th registered.
Novartis’s Anemia, Aplastic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 14 in Anemia, Aplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA). Treatment with eltrombopag was started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. The hematological response rate was assessed at 3, 6 months and 1 year after starting the study treatment (Week 13, 26 and 52).
This was a bridging study to support China registration. An estimation strategy rather than a formal hypothesis testing was pursued. Twenty subjects were enrolled into the study.
Treatment with eltrombopag started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count, up to 150 mg/day. Hematological response rate was assessed at 3, 6 months and 1 year (Week 13, 26 and 52) after starting the study treatment. Subjects in whom the treatment was found to be effective at 6 months continued to receive the treatment. Eltrombopag was discontinued if the treatment was ineffective at 6 months. Subjects discontinued eltrombopag before 6 months if any of the treatment discontinuation criteria was met.
Analysis set for the primary endpoint was Full Analysis Set (FAS) and subjects who discontinue from the study before Week 26 were treated as non-responders in the response analysis. Eltrombopag treatment was provided to subjects who were considered to require continued treatment at Week 26. After Week 26, if all of the hematologic response criteria (i.e., platelet count > 50×109/L, hemoglobin level > 100 g/L without transfusion, and neutrophil count > 1.0×109/L) remained fulfilled for more than 8 weeks, the dose of eltrombopag was decreased by half. If the response continued for further 8 weeks even at the decreased dose, the treatment was discontinued. If a decrease in any of the hematologic values (i.e., platelet count \< 30×109/L, hemoglobin \< 90 g/L, or neutrophil count \< 0.5×109/L) was found after dose reduction, the dose was increased to the previous level. Furthermore, after treatment interruption, the treatment was restarted if any of the hematologic values decreased to the above-mentioned levels. The response assessment and safety evaluation were performed at Week 52.
The Extension part of this study started 1 year (Week 52) after the initiation of study treatment. This part was included in the study with an ethical consideration for subjects who required continued treatment. The continued treatment was provided up to the launch of eltrombopag after approval. Follow-up visit was performed 30 days after the discontinuation of eltrombopag treatment.
To better understand the pharmacokinetics (PK) characteristics of eltrombopag in Chinese severe aplastic anemia (SAA) patient population, intensive PK blood samples were collected only in the initial 12 Chinese subjects receiving 25 mg/day dose after reaching steady-state, to provide evaluable full PK profiles. Steady-state trough concentrations were collected at other dose levels and in other subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects started eltrombopag treatment at 25 mg/day since Day 1.
Drug: Eltrombopag
Eltrombopag are film-coated tablets containing 25 mg of eltrombopag free acid in each tablet.
Also known as: ETB115
Hematologic Response Rate at 6 Months (Week 26) by Investigator
Hematologic response rate: percentage of subjects who met any of the International Working Group criteria: Platelet count: If platelet transfusion independent at baseline (BL): Transfusion independent and increase from BL by 20×10\^9/L or more; If platelet transfusion dependent at BL: No platelet transfusion requirement for 8 weeks; Hemoglobin: If red blood cells (RBC) transfusion independent at BL: transfusion independent and increase from BL by 15 g/L or more; If RBC transfusion dependent at BL: A decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period (1 unit = RBC derived from 200 mL blood) or no RBC transfusion requirement for 8 weeks; Neutrophil count: In the absence of granulocyte colony stimulating factor (G-CSF) taken within 21 days preceding the blood sample collection: Increase from BL by 0.5×10\^9/L or more, or (if \< 0.5×10\^9/L at BL) increase by 100% or more. Patients who discontinued from the trial before week 26 were treated as non-responders.
Time frame: 6 months (Week 26)
Hematologic Response Rate by Investigator
Hematologic response rate: percentage of subjects who met any of the International Working Group criteria: Platelet count: If platelet transfusion independent at baseline (BL): Transfusion independent and increase from BL by 20×10\^9/L or more; If platelet transfusion dependent at BL: No platelet transfusion requirement for 8 wks; Hemoglobin: If red blood cells (RBC) transfusion independent at BL: transfusion independent and increase from BL by 15 g/L or more; If RBC transfusion dependent at BL: A decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period (1 unit =RBC derived from 200 mL blood) or no RBC transfusion requirement for 8 wks; Neutrophil count: In the absence of granulocyte colony stimulating factor (G-CSF) taken within 21 days preceding the blood sample collection: Increase from BL by 0.5×10\^9/L or more, or (if \< 0.5×10\^9/L at BL) increase by 100% or more. Patients who discontinued from the trial before wks 13 \& 26 were treated as non-responders.
Time frame: Week (Wk) 13, Week 52
Change From Baseline in Platelet Count
Change (increase from baseline) in platelet count (in the absence of platelet transfusion) were calculated according to the lab test results entered into the case report form (CRF) that were summarized at each visit using descriptive statistics. Platelet Count (×109/L) was assessed in hematology test.
Time frame: Baseline, Week 13, Week 26, Week 52
Change From Baseline in Hemoglobin Levels
Change (increase from baseline) in hemoglobin (in the absence of red blood cell (RBC) transfusion) were calculated according to the lab test results entered into the CRF that were summarized at each visit using descriptive statistics. Hemoglobin level (g/L) was assessed in hematology test.
Time frame: Baseline, Week 13, Week 26 and Week 52
Change From Baseline in Neutrophil Count
Change (increase from baseline) in neutrophil count (in the absence of granulocyte colony stimulating factor (G-CSF) and calculated according to the lab test results entered into the CRF that were summarized at each visit using descriptive statistics). Neutrophil count (×109/L) was assessed in hematology test.
Time frame: Baseline, Week 13, Week 26 and Week 52
Time to Hematologic Response by Investigator
Time to hematological response was defined as the time from the date of first study drug administration to the first hematological response. If a participant did not meet hematological response before or at the cutoff date, censoring was performed using the date of last assessment.
Time frame: Baseline to Week 26
Duration of Hematologic Response by Investigator
Duration of hematologic response (any response according to the response criteria for the primary endpoint). For subjects who responded, duration of response was defined as the number of weeks from the first date of hematological response until the first date of relapse or death. Only participants with at least two response assessments were included for the duration of hematologic response assessment.
Time frame: up to approx. 3.5 years
Frequency of Platelets Transfusion
For subjects receiving transfusion (platelets) at baseline, the frequency of platelet transfusion in each period (Baseline: 4 weeks before Day 1; Week 13, 26, 52: 4 weeks before each visit day) was summarized using descriptive statistics.
Time frame: Baseline, Week 13, Week 26 and Week 52
Amount of Platelets Transfusion
The amount of transfusion was defined as the sum of transfusion multiplied by the volume of transfusion.
Time frame: Baseline, Week 13, Week 26 and Week 52
Frequency of Red Blood Cells (RBC) Transfusion
For subjects receiving transfusion (RBC (Red Blood Cell)) at baseline, the frequency of RBC transfusion in each period (Baseline: 8 weeks before Day 1; Week 13, 26, 52: 8 weeks before each visit day) was summarized using descriptive statistics.
Time frame: Baseline, Week 13, Week 26 and Week 52
Amount of Red Blood Cells (RBC) Transfusion
The amount of RBC transfusion was defined as the sum of transfusion multiplied by the volume of transfusion.
Time frame: Baseline, Week 13, Week 26 and Week 52
Plasma PK Parameters of Eltrombopag: Cmax
Cmax is the maximum (peak) observed plasma drug concentration after single dose administration (mass\*volume-1). Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.
Time frame: pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14
Plasma PK Parameters of Eltrombopag: Tmax
Tmax is the time to reach maximum (peak) plasma drug concentration after single dose administration (time). Blood samples were collected from all patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.
Time frame: pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14
Plasma PK Parameters of Eltrombopag: AUCtau & AUClast
AUCtau is the area under the curve calculated to the end of a dosing interval (tau) at steady-state (amount\*time\*volume-1). AUClast is the AUC calculated from time 0 to the time of the last quantifiable concentration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.
Time frame: pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14
Plasma PK Parameters of Eltrombopag: CLss/F
Steady State (CLss/F) is the apparent systemic (or total body) clearance at steady state from plasma (volume/time) following drug administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.
Time frame: pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14
Plasma Trough Concentration of Eltrombopag
Ctrough is the pre-dose concentration at the end of dose interval (mass\*volume-1). Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state. Sparse PK blood samples were collected for the other doses and in the rest of the patients for Ctrough assessment.
Time frame: Pre-dose sample on the 15th day after each new dose level was started
Number of Participants With Clonal Evolution
Number of participants with clonal evolution with a normal karyotype at baseline including clonal evolution to PNH (Paroxysmal Nocturnal Hemoglobinuria), evolution to AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes).
Time frame: From Baseline up to approx. 2.9 years
The study enrolled all 20 participants from 5 sites in China.
| Milestone | Eltrombopag |
|---|---|
| Started | 20 |
| Completed 26-week treatment phase | 17 |
| Entered week 52 treatment phase | 15 |
| Completed week 52 treatment phase | 14 |
| Completed | 14 |
| Not completed | 6 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Death | 1 |
Hematologic response rate: percentage of subjects who met any of the International Working Group criteria: Platelet count: If platelet transfusion independent at baseline (BL): Transfusion independent and increase from BL by 20×10\^9/L or more; If platelet transfusion dependent at BL: No platelet transfusion requirement for 8 weeks; Hemoglobin: If red blood cells (RBC) transfusion independent at BL: transfusion independent and increase from BL by 15 g/L or more; If RBC transfusion dependent at BL: A decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period (1 unit = RBC derived from 200 mL blood) or no RBC transfusion requirement for 8 weeks; Neutrophil count: In the absence of granulocyte colony stimulating factor (G-CSF) taken within 21 days preceding the blood sample collection: Increase from BL by 0.5×10\^9/L or more, or (if \< 0.5×10\^9/L at BL) increase by 100% or more. Patients who discontinued from the trial before week 26 were treated as non-responders.
| Percentage of participants | Eltrombopag |
|---|---|
| Hematologic Response Rate at 6 Months (Week 26) by Investigator | 70.0 (49.2 to 86.0) |
Hematologic response rate: percentage of subjects who met any of the International Working Group criteria: Platelet count: If platelet transfusion independent at baseline (BL): Transfusion independent and increase from BL by 20×10\^9/L or more; If platelet transfusion dependent at BL: No platelet transfusion requirement for 8 wks; Hemoglobin: If red blood cells (RBC) transfusion independent at BL: transfusion independent and increase from BL by 15 g/L or more; If RBC transfusion dependent at BL: A decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period (1 unit =RBC derived from 200 mL blood) or no RBC transfusion requirement for 8 wks; Neutrophil count: In the absence of granulocyte colony stimulating factor (G-CSF) taken within 21 days preceding the blood sample collection: Increase from BL by 0.5×10\^9/L or more, or (if \< 0.5×10\^9/L at BL) increase by 100% or more. Patients who discontinued from the trial before wks 13 \& 26 were treated as non-responders.
| Percentage of participants | Eltrombopag |
|---|---|
| Week 13 | 65.0 (44.2 to 82.3) |
| Week 52 | 65.0 (44.2 to 82.3) |
Change (increase from baseline) in platelet count (in the absence of platelet transfusion) were calculated according to the lab test results entered into the case report form (CRF) that were summarized at each visit using descriptive statistics. Platelet Count (×109/L) was assessed in hematology test.
| 10^9 platelets/liter | Eltrombopag |
|---|---|
| Baseline (BL) | 10.725 ± 7.8731 |
| Change from BL at Week 13/Day92 | 10.265 ± 14.1456 |
| Change from BL at Week 26/Day 183 | 26.933 ± 30.5304 |
| Change from BL at Week 52/Day 365 | 41.071 ± 56.6816 |
Change (increase from baseline) in hemoglobin (in the absence of red blood cell (RBC) transfusion) were calculated according to the lab test results entered into the CRF that were summarized at each visit using descriptive statistics. Hemoglobin level (g/L) was assessed in hematology test.
| gram/liter | Eltrombopag |
|---|---|
| Baseline | 66.9 ± 19.90 |
| Change from BL at Week 13/Day92 | 22.4 ± 23.47 |
| Change from baseline at Week 26/Day 183 | 31.9 ± 29.20 |
| Change from BL at Week 52/Day 365 | 32.9 ± 33.21 |
Change (increase from baseline) in neutrophil count (in the absence of granulocyte colony stimulating factor (G-CSF) and calculated according to the lab test results entered into the CRF that were summarized at each visit using descriptive statistics). Neutrophil count (×109/L) was assessed in hematology test.
| 10^9 neutrophils/liter | Eltrombopag |
|---|---|
| Baseline | 1.199 ± 1.3483 |
| Change from BL at Week 13/Day 92 (n = 16) | -0.160 ± 1.4141 |
| Change from baseline at Week 26/Day 183 (n = 14) | 0.196 ± 1.6822 |
| Change from BL at Week 52/Day 365 (n = 14) | 0.447 ± 1.5764 |
Time to hematological response was defined as the time from the date of first study drug administration to the first hematological response. If a participant did not meet hematological response before or at the cutoff date, censoring was performed using the date of last assessment.
| Weeks | Eltrombopag |
|---|---|
| Time to Hematologic Response by Investigator | 10.0 (8.0 to 12.0) |
Duration of hematologic response (any response according to the response criteria for the primary endpoint). For subjects who responded, duration of response was defined as the number of weeks from the first date of hematological response until the first date of relapse or death. Only participants with at least two response assessments were included for the duration of hematologic response assessment.
| Weeks | Eltrombopag |
|---|---|
| Duration of Hematologic Response by Investigator | NA (22.3 to NA) |
For subjects receiving transfusion (platelets) at baseline, the frequency of platelet transfusion in each period (Baseline: 4 weeks before Day 1; Week 13, 26, 52: 4 weeks before each visit day) was summarized using descriptive statistics.
| occurrences | Eltrombopag |
|---|---|
| Baseline | 1.8 ± 1.32 |
| Week 13 | 0.4 ± 0.88 |
| Week 26 | 0.1 ± 0.35 |
| Week 52 | 0.0 ± 0.00 |
The amount of transfusion was defined as the sum of transfusion multiplied by the volume of transfusion.
| Units | Eltrombopag |
|---|---|
| Baseline | 3.7 ± 3.63 |
| Week 13 | 0.4 ± 0.88 |
| Week 26 | 0.1 ± 0.35 |
| Week 52 | 0.0 ± 0.00 |
For subjects receiving transfusion (RBC (Red Blood Cell)) at baseline, the frequency of RBC transfusion in each period (Baseline: 8 weeks before Day 1; Week 13, 26, 52: 8 weeks before each visit day) was summarized using descriptive statistics.
| occurrences | Eltrombopag |
|---|---|
| Baseline | 3.0 ± 2.04 |
| Week 13 | 1.8 ± 2.83 |
| Week 26 | 1.5 ± 2.02 |
| Week 52 | 0.5 ± 0.71 |
The amount of RBC transfusion was defined as the sum of transfusion multiplied by the volume of transfusion.
| Units | Eltrombopag |
|---|---|
| Baseline | 6.6 ± 4.16 |
| Week 13 | 3.8 ± 6.18 |
| Week 25 | 3.0 ± 4.02 |
| Week 52 | 1.4 ± 1.90 |
Cmax is the maximum (peak) observed plasma drug concentration after single dose administration (mass\*volume-1). Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.
| ng/mL | Eltrombopag |
|---|---|
| Plasma PK Parameters of Eltrombopag: Cmax | 3450 ± 1900 |
Tmax is the time to reach maximum (peak) plasma drug concentration after single dose administration (time). Blood samples were collected from all patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.
| hour | Eltrombopag |
|---|---|
| Plasma PK Parameters of Eltrombopag: Tmax | 3.73 (0.917 to 5.90) |
AUCtau is the area under the curve calculated to the end of a dosing interval (tau) at steady-state (amount\*time\*volume-1). AUClast is the AUC calculated from time 0 to the time of the last quantifiable concentration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.
| h*ng/mL | Eltrombopag |
|---|---|
| AUCtau | 67900 ± 31400 |
| AUClast | 62700 ± 33200 |
Steady State (CLss/F) is the apparent systemic (or total body) clearance at steady state from plasma (volume/time) following drug administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.
| L/h | Eltrombopag |
|---|---|
| Plasma PK Parameters of Eltrombopag: CLss/F | 0.441 ± 0.178 |
Ctrough is the pre-dose concentration at the end of dose interval (mass\*volume-1). Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state. Sparse PK blood samples were collected for the other doses and in the rest of the patients for Ctrough assessment.
| ng/mL | Eltrombopag |
|---|---|
| concentration at 25 mg | 2180 ± 1490 |
| concentration at 50 mg | 5180 ± 3320 |
| concentration at 75 mg | 11300 ± 6000 |
| concentration at 100 mg | 14700 ± 8070 |
| concentration at 125 mg | 20300 ± 11300 |
| concentration at 150 mg | 23800 ± 13700 |
Number of participants with clonal evolution with a normal karyotype at baseline including clonal evolution to PNH (Paroxysmal Nocturnal Hemoglobinuria), evolution to AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes).
| Participants | Eltrombopag |
|---|---|
| Number of Participants With Clonal Evolution | 2 |
Deaths were collected from the first dose until end of study, a maximum duration of up to 3.5 years. On-treatment deaths were collected within 30 days of the last dose, while post-treatment deaths were collected more than 30 days after the last dose for those who discontinued treatment early. Adverse events were collected from the first dose until 30 days after the last dose, also up to a maximum duration if 3.5 years. Adverse Events were not collected in the post-treatment period.
| Participants | Eltrombopag |
|---|---|
| All Deaths | 1 |
| On-treatment deaths | 0 |
| Post-treatment deaths | 1 |
Collected over Deaths were collected from the first dose until end of study, a maximum duration of up to 3.5 years. On-treatment deaths were collected within 30 days of the last dose, while post-treatment deaths were collected more than 30 days after the last dose for those who discontinued treatment early. Adverse events were collected from the first dose until 30 days after the last dose, also up to a maximum duration if 3.5 years. Adverse Events were not collected in the post-treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag (On-treatment) | 0/20 (0%) | 8/20 (40%) | 19/20 (95%) |
| Eltrombopag (Post-treatment) | 1/20 (5%) | — | — |
| Event | Eltrombopag (On-treatment) | Eltrombopag (Post-treatment) |
|---|---|---|
| PneumoniaInfections and infestations | 3/20 | — |
| Upper respiratory tract infectionInfections and infestations | 2/20 | — |
| Intentional product misuseInjury, poisoning and procedural complications | 2/20 | — |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/20 | — |
| GastritisGastrointestinal disorders | 1/20 | — |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/20 | — |
| PyrexiaGeneral disorders | 1/20 | — |
| Liver injuryHepatobiliary disorders | 1/20 | — |
| Spermatic cord funiculitisInfections and infestations | 1/20 | — |
| Groin painMusculoskeletal and connective tissue disorders | 1/20 | — |
| Event | Eltrombopag (On-treatment) | Eltrombopag (Post-treatment) |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 8/20 | — |
| Blood creatinine increasedInvestigations | 6/20 | — |
| PyrexiaGeneral disorders | 5/20 | — |
| HyperbilirubinaemiaHepatobiliary disorders | 5/20 | — |
| HyperuricaemiaMetabolism and nutrition disorders | 5/20 | — |
| Hepatic function abnormalHepatobiliary disorders | 4/20 | — |
| Blood glucose increasedInvestigations | 4/20 | — |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 4/20 | — |
| Oedema peripheralGeneral disorders | 3/20 | — |
| Liver injuryHepatobiliary disorders | 3/20 | — |
Full Analysis Set (FAS) comprised all patients to whom study treatment had been assigned and received one dose of study treatment.
| Age, Continuous(years) | Eltrombopag |
|---|---|
| Mean | 39.0 ± 13.25 |
| Sex: Female, Male(Participants) | Eltrombopag |
|---|---|
| Female | 5 |
| Male | 15 |
| Race/Ethnicity, Customized(Participants) | Eltrombopag |
|---|---|
| Asian | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Dec 2019 to primary completion in Jul 2021, 19 months.
Results were first posted in Feb 2025, 3 years 6 months after primary completion.
Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag